Plerixa 24 mg Injection 1.2 ml

Plerixa 24 mg Injection 1.2 ml belongs to the class of hemopoietic stem cell mobilizer. It is used in the treatment of Non-Hodgkin’s Disease (a blood cancer that affects your lymph system) and multiple myeloma (a type of cancer that affects the plasma cells of the bone marrow) in combination with granulocyte-colony stimulating factor (G-CSF).

Plerixa 24 mg Injection 1.2 ml contains Plerixafor, which belongs to the hemopoietic stem cell mobilizer class or drugs. It works by binding to the chemokine receptor CXCR4 and inhibits the binding of its cognate ligand CXCL12.

Plerixa 24 mg Injection 1.2 ml may cause certain side effects, such as nausea, vomiting, headache, dizziness, diarrhoea, flatulence, fatigue, and pain at the site of injection. These side effects do not require medical attention and gradually resolve over time. A trained healthcare professional will administer it. Do not self-administer.

Avoid taking it and inform your doctor if you are allergic to Plerixa 24 mg Injection 1.2 ml or its components. Before administration, inform your doctor if you have liver/kidney disease, cardiac disorders, blood disorders or respiratory conditions. This medicine is known to cause fetal harm in pregnant women. Hence, inform your doctor if you are pregnant or are planning to become pregnant. Breastfeeding should be discontinued during the treatment.

Plerixa 24 mg Injection 1.2 ml contains Plerixafor, which belongs to the hemopoietic stem cell mobilizer class or drugs. It works by binding to the chemokine receptor CXCR4 and inhibiting its cognate ligand CXCL12 binding. This mobilizes hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in cancer patients.

Plerixa 24 mg Injection 1.2 ml should be avoided if you are allergic to it or any other components present in it. Let your doctor know about your complete medical history, including current medication, to rule out any side effects/interactions. Before administration, inform your doctor if you have liver/kidney disease, cardiac disorders, blood disorders, anaemia, or respiratory conditions. Plerixa 24 mg Injection 1.2 ml may cause the potential for tumor cell mobilization in leukemia patients, haematological effects, and splenic rupture in some patients. Hence, careful monitoring should be done during the entire treatment. This medicine is known to cause fetal harm in pregnant women. Hence, inform your doctor if you are pregnant or are planning to become pregnant. Breastfeeding should be discontinued in nursing mothers during the treatment. Plerixa 24 mg Injection 1.2 ml should be avoided in children as safety is not established.

• A blood test should be performed, such as LFT, RFT, and PFT, to check for liver function and pulmonary function.
• Weekly blood tests should be done during the treatment to check for CBC (Complete blood count).